ANX anadis limited

Biotech for the little black book

  1. 470 Posts.
    ANADIS LIMITED 2002-08-21 ASX-SIGNAL-G

    HOMEX - Melbourne

    +++++++++++++++++++++++++
    Anadis Limited is pleased to announce that the Industry Research and
    Development Board of AusIndustry has approved a funding grant to
    Anadis Limited for $250,000 under the Biotech Innovation Fund. This
    will assist Anadis to undertake research into the efficacy of the
    Anadis "Bioshielding" technology. The Biotech Innovation Fund is a
    Commonwealth government program that encourages the commercialization
    of promising biotechnology developed in Australia.

    The research will primarily be aimed at demonstrating the protective
    ability of the "Bioshielding" technology to protect beneficial
    bacteria (probiotics) in a range of gut-benefit foods. Probiotics
    are human friendly bacteria that can be used to "crowd out"
    pathogenic gut bacteria and thereby promote the health of the
    digestive tract. Examples of probiotic bacteria are bacteria present
    in natural yogurts and fermented drinks.

    The successful completion of this proof of concept project will
    demonstrate "Bioshield's" effectiveness in the delivery of high
    counts of fast growing probiotic bacteria to the intestine, and will
    result in the rapid uptake of the technology by the food industry to
    enhance the health benefits of existing products.

    Anadis welcomes a new employee, Dr Victor Wang, our new senior
    protein chemist. His expertise will be invaluable for this project as
    well as other projects Anadis has underway. Dr Wong will also bring
    many years of experience to our product development team with his
    background in the commercial manufacture of proteins and the
    fermentation of bacteria.

    Also joining as a full time employee is Brian Muller. Brian brings
    with him his comprehensive background in commercial protein
    manufacturing. Brian will take up the position as Manager of Quality
    Assurance to enable Anadis to meet the stringent requirements for
    pharmaceutical manufacture.

    C Graham
    MANAGING DIRECTOR & CEO

    For Further information contact:

    Mr Conor Graham or Dr Grant Rawlin
    Telephone: 03 9358 6388
    Facsimile: 03 9358 6399
    Email: [email protected]
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.